Epibatidine: high potency and broad spectrum activity on neuronal and neuromuscular nicotinic acetylcholine receptors.
The activity of epibatidine at neuronal and neuromuscular nicotinic acetylcholine receptors was investigated in several in situ and in vitro systems and compared with the activity of nicotine and suxamethonium. Activation of ganglionic nicotinic receptors by epibatidine was shown in the guinea-pig ileum (contraction mediated by the cholinergic neurons of the ileum) and in pithed and atropinized rats (rise in blood pressure). Epibatidine also activated nicotinic receptors at the peripheral terminals of afferent C-fibres (rabbit ear) and in the brain (antidiuresis in rats). The agonistic effects of epibatidine were followed by long-lasting receptor desensitization. No antinociceptive effect of epibatidine was seen in rats at a dose free of motor impairment. On muscle end plate nicotinic receptors of the rat diaphragm (not responding to depolarizing agents by contraction), epibatidine was equipotent with suxamethonium in causing neuromuscular inhibition. On an extraocular muscle of the rabbit (responding to depolarizing agents by contraction) epibatidine in vitro and in situ caused a contraction at a 100-fold lower dose than suxamethonium. The Straub tail reaction in mice to epibatidine could be attributed to the sustained stimulation of motor end plate receptors of the "slow contracting" type of muscle fibres by epibatidine. In conclusion epibatidine was the most potent agonist on all neuronal and neuromuscular nicotinic receptors examined.
Lembeck
F
F
Institut für experimentelle und klinische Pharmakologie, Graz, Austria.
D000818:Animals; D001306:Auditory Pathways / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology*; D003655:Decerebrate State; D005260:Female; D005728:Ganglia, Sympathetic / Q000378:metabolism; D006168:Guinea Pigs; D007082:Ileum; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D009119:Muscle Contraction; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000378:metabolism*; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology*; D009801:Oculomotor Muscles / Q000378:metabolism; D017288:Pain Threshold / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000187:drug effects*; D013390:Succinylcholine / Q000494:pharmacology; D017779:Sympathetic Fibers, Postganglionic / Q000378:metabolism
D019086:Bridged Bicyclo Compounds, Heterocyclic; D009467:Neuromuscular Depolarizing Agents; D018722:Nicotinic Agonists; D011725:Pyridines; D011978:Receptors, Nicotinic; D009538:Nicotine; D013390:Succinylcholine; C082748:epibatidine